{"nctId":"NCT01847313","briefTitle":"The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease","startDateStruct":{"date":"2013-04"},"conditions":["Diabetic Kidney Disease"],"count":20,"armGroups":[{"label":"Liraglutide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Liraglutide"]},{"label":"Control","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Liraglutide","otherNames":["Glucagon like peptide 1 receptor agonist","NN2211"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes with a HbA1c of 42-75mmol/mol (6-9%DCCT)\n* Male or female aged above 30 years\n* Have a negative pregnancy test at screening (women of child bearing potential only)\n* Body mass index (BMI) of 25kg/m2 or greater\n* On a renin-angiotensin system antagonist, at a stable dose, for at least 8 weeks before inclusion into the study\n* Established microalbuminuria\n* Estimated glomerular filtration rate (eGFR) 30ml/min/1.73m2 or above by Modification of Diet in Renal Disease (MDRD) formula\n\nExclusion Criteria:\n\n* Patients with any cognitive impediment that preclude the patient from giving free and informed consent\n* Patients on dipeptidyl peptidase 4 inhibitors or thiazolidinedione treatment\n* Patients with stage 4-5 renal disease, defined as an eGFR of 30ml/min/1.73m2 or less\n* Patients who have used a GLP-1 agent in the last 6 months\n* Female patients of child bearing potential who are pregnant, breastfeeding, or unwilling to practice an acceptable barrier and/or hormonal method of contraception or abstinence during participation in the study\n* Previous pancreatitis\n* Hypersensitivity to GLP-1 analogues\n* Proliferative diabetic retinopathy\n* Any other contraindications, as per the SmPC for liraglutide\n* Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the dosing requirements\n* Concurrent treatment with an investigational drug or participation in another clinical trial\n* Use of an investigational drug within 4 weeks or 5 half-lives, whichever is longer, preceding the first dose of investigational medicinal product","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"MCP-1:Creatinine Ratio in Urine","description":"Spot urine sample for MCP-1 and creatinine","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":"14.3"},{"groupId":"OG001","value":"24.3","spread":"15.4"}]}]}]},{"type":"SECONDARY","title":"Urine Albumin:Creatinine Ratio","description":"Spot urine sample for albumin and creatinine","classes":[]},{"type":"SECONDARY","title":"Urinary Albumin Excretion Rate","description":"Albuminuria as Measured by 24 Hour Albumin Excretion Rate","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144.1","spread":"232.6"},{"groupId":"OG001","value":"132.4","spread":"101.3"}]}]}]},{"type":"SECONDARY","title":"sCD163 in Serum","description":"Serum sample for sCD163","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":"34"},{"groupId":"OG001","value":"84","spread":"23"}]}]}]},{"type":"SECONDARY","title":"sCD163:Creatinine Ratio in Urine","description":"Spot urine sample for MCP-1 and creatinine","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9","spread":"14.0"},{"groupId":"OG001","value":"24.3","spread":"15.4"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Safety in All Participants as Measured by Adverse Event Rate","description":"Adverse event data collection","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":10},"commonTop":["Hypoglycaemia","Acute kidney injury","Hypokalaemia","Diarrhoea","Gastroenteritis"]}}}